Treatment with a drug known to cause calculogenesis in the urinary tract

Renal stone disease - Treatment with a drug known to cause calculogenesis in the urinary tract Factor

Last reviewed for CCPS 01 August 1995.

Investigative Documents

Medical Report - Drugs Known to Cause Calculogenesis - Nephrolithiasis [MR9054]

Preliminary questions [11106]

11206

there is some evidence that treatment with a drug known to play a role in calculogenesis in the urinary tract may be a factor in the development of the condition under consideration.

11207 the veteran has taken a drug known to play a role in calculogenesis in the urinary tract at some time.

11209

the treatment with the drug known to play a role in calculogenesis in the urinary tract continued for at least 90 days.

11210

the treatment with the drug known to play a role in calculogenesis in the urinary tract continued for at least 90 days before the clinical onset of the condition under consideration.

11208

the veteran's treatment with a drug known to play a role in calculogenesis in the urinary tract for at least 90 days was materially contributed to by treatment of an illness or injury which is identifiable.

11211 — the veteran has established the temporal connection between the identified illness or injury which materially contributed to the treatment with the drug known to play a role in calculogenesis in the urinary tract and VEA service for the clinical onset of the condition under consideration.

11217

the clinical onset of the condition under consideration occurred while treatment with the drug known to play a role in calculogenesis in the urinary tract for at least 90 days, to which the identified illness or injury made a material contribution, continued.

or

11218

the clinical onset of the condition under consideration occurred within the 180 days after the cessation of treatment with the drug known to play a role in calculogenesis in the urinary tract for at least 90 days, to which the identified illness or injury made a material contribution.

11212 — the veteran has established the causal connection between the identified illness or injury which materially contributed to the treatment with the drug known to play a role in calculogenesis in the urinary tract and VEA service for the clinical onset of the condition under consideration.

11213 — the veteran has established the causal connection between the identified illness or injury which materially contributed to the treatment with the drug known to play a role in calculogenesis in the urinary tract and operational service for the clinical onset of the condition under consideration.

or

11214 — the veteran has established the causal connection between the identified illness or injury which materially contributed to the treatment with the drug known to play a role in calculogenesis in the urinary tract and eligible service for the clinical onset of the condition under consideration.

Clinical onset and operational service [11213]

11215 — the identified illness or injury, which materially contributed to the veteran's treatment with the drug known to play a role in calculogenesis in the urinary tract for at least 90 days, is causally related to operational service.

Clinical onset and eligible service [11214]

11216 — the identified illness or injury, which materially contributed to the veteran's treatment with the drug known to play a role in calculogenesis in the urinary tract for at least 90 days, is causally related to eligible service.